کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6117663 | 1591768 | 2015 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function
ترجمه فارسی عنوان
تجزیه و تحلیل فارماکوکینتیک / فارماکودینامیک برای ارزیابی رژیمهای دارویی سفترولین فوزامیل برای درمان پنومونی باکتریایی جامعه و ساختار عفونت های پوستی و پوستی در بیماران مبتلا به اختلال عملکرد کلیوی
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
میکروبیولوژی و بیوتکنولوژی کاربردی
چکیده انگلیسی
In this study, the probability of pharmacokinetic/pharmacodynamic target attainment (PTA) of ceftaroline against clinical isolates causing community-acquired bacterial pneumonia (CABP) and complicated skin and skin-structure infection (cSSSI) in Europe was evaluated. Three dosing regimens were assessed: 600Â mg every 12Â h (q12Â h) as a 1-h infusion (standard dose) or 600Â mg every 8Â h (q8Â h) as a 2-h infusion in virtual patients with normal renal function; and 400Â mg q12Â h as a 1-h infusion in patients with moderate renal impairment. Pharmacokinetic and microbiological data were obtained from the literature. The PTA and the cumulative fraction of response (CFR) were calculated by Monte Carlo simulation. In patients with normal renal function, the ceftaroline standard dose (600Â mg q12Â h as a 1-h infusion) can be sufficient to treat CABP due to ceftazidime-susceptible (CAZ-S) Escherichia coli, CAZ-S Klebsiella pneumoniae, meticillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis (CFRÂ >Â 90%). However, against meticillin-resistant S. aureus (MRSA), the CFR was 72%. In cSSSI, the CFR was also <80% for MRSA. Administration of ceftaroline 600Â mg q8Â h as a 2-h infusion or 400Â mg q12Â h as a 1-h infusion in patients with moderate renal insufficiency provided a high probability of treatment success (CFR ca. 100%) for most micro-organisms causing CABP and cSSSI, including MRSA and penicillin-non-susceptible S. pneumoniae. These results suggest that in patients with normal renal function, ceftaroline 600Â mg q8Â h as a 2-h infusion may be a better option than the standard dose, especially if the MRSA rate is high.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: International Journal of Antimicrobial Agents - Volume 45, Issue 4, April 2015, Pages 399-405
Journal: International Journal of Antimicrobial Agents - Volume 45, Issue 4, April 2015, Pages 399-405
نویسندگان
A. Canut, A. Isla, A. RodrÃguez-Gascón,